Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG intergroup phase 2 study.

被引：0
|
作者：
Berg, SL
Blaney, SM
Bernstein, M
Kurtzberg, J
Devidas, M
Lampkin, T
Murgo, AJ
Harris, MB
机构：
[1] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[2] Hop St Justine, Montreal, PQ H3T 1C5, Canada
[3] Duke Univ, Med Ctr, Durham, NC 27706 USA
[4] Childrens Oncol Grp, Gainesville, FL USA
[5] GlaxoSmithKline, Collegeville, PA USA
[6] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Rockville, MD USA
[7] Hackensack Univ, Tomorrow Childrens Inst, Med Ctr, Hackensack, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
792
引用
收藏
页码：226A / 226A
页数：1
相关论文
共 50 条
  • [1] Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-Cell malignancies: A report from the children's oncology group
    Berg, SL
    Blaney, SM
    Devidas, M
    Lampkin, TA
    Murgo, A
    Bernstein, M
    Billett, A
    Kurtzberg, J
    Reaman, G
    Gaynon, P
    Whitlock, J
    Krailo, M
    Harris, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3376 - 3382
  • [2] Results of a phase II study of 506U78 (Nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma
    Thompson, MA
    Pro, B
    Sarris, A
    Hagemeister, FB
    Goy, A
    Bleyer, A
    Cabanillas, FF
    Samaniego, F
    Fayad, LE
    BLOOD, 2005, 106 (11) : 753A - 753A
  • [3] Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901
    Czuczman, Myron S.
    Porcu, Pierluigi
    Johnson, Jeffrey
    Niedzwiecki, Donna
    Kelly, Michael
    Hsi, Eric D.
    Cook, James R.
    Canellos, George
    Cheson, Bruce D.
    LEUKEMIA & LYMPHOMA, 2007, 48 (01) : 97 - 103
  • [4] Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies
    Kurtzberg, J
    Ernst, TJ
    Keating, MJ
    Gandhi, V
    Hodge, JP
    Kisor, DF
    Lager, JJ
    Stephens, C
    Levin, J
    Krenitsky, T
    Elion, G
    Mitchell, BS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3396 - 3403
  • [5] Phase II study of compound GW506U78 (AraG) in patients with T-cell and B-cell non Hodgkin lymphomas (NHL).
    Goy, A
    Sarris, AH
    Bleyer, A
    Duvic, M
    Mesina, O
    Dang, NH
    Fayad, L
    Hagemeister, F
    McLaughlin, P
    Pro, B
    Rodriguez, MA
    Romaguera, J
    Samagieno, F
    Younes, A
    BLOOD, 2002, 100 (11) : 304B - 304B
  • [6] Phase II study of compound GW506U78 (AraG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy
    Goy, A
    Bleyer, A
    Hagemeister, F
    Fayad, L
    Pro, B
    Romaguera, J
    Samaniego, F
    Sarris, AH
    Hart, S
    Cabanillas, F
    Murgo, A
    Duvic, M
    Rodriguez, MA
    BLOOD, 2003, 102 (11) : 639A - 639A
  • [7] 2-amino-9-B-D-arabinosyl-6-methoxy-9H-guanine (GW 506U; compound 506U) is highly active in patients with T-cell malignancies: Results of a phase I trial in pediatric and adult patients with refractory hematological malignancies.
    Kurtzberg, J
    Keating, M
    Moore, JO
    Gandhi, V
    Blaney, S
    Gold, S
    Ernst, T
    HensleeDowney, J
    Chang, A
    Kisor, D
    Plunkett, W
    Mitchell, B
    BLOOD, 1996, 88 (10) : 2666 - 2666
  • [8] A Phase I study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies.
    Kurtzberg, J
    Ernst, TJ
    Keating, MJ
    Gandhi, V
    Hodge, JP
    Kisor, DF
    Therriault, R
    Stephens, C
    Levin, J
    Krenitsky, T
    Elion, GB
    Mitchell, BS
    BLOOD, 1999, 94 (10) : 629A - 629A
  • [9] A phase II study of 2-amino-β-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL):: CALGB study 19801.
    De Angelo, DJ
    Yu, DH
    Dodge, RK
    Coutre, SE
    Mitchell, BS
    Stone, RM
    Stopeck, AT
    Larson, RA
    BLOOD, 2002, 100 (11) : 198A - 198A
  • [10] Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
    Kim, Won-Seog
    Fukuhara, Noriko
    Yoon, Dok-Hyun
    Yamamoto, Kazuhito
    Uchida, Toshiki
    Negoro, Eiju
    Izutsu, Koji
    Terui, Yasuhito
    Nakajima, Hideaki
    Ando, Kiyoshi
    Suehiro, Youko
    Kang, Hye Jin
    Ko, Po-Shen
    Nagahama, Fumiko
    Sonehara, Yusuke
    Nagai, Hirokazu
    Tien, Hwei-Fang
    Kwong, Yok-Lam
    Tobinai, Kensei
    BLOOD ADVANCES, 2023, 7 (17) : 4903 - 4912
12345